Does the Syk Inhibitor Fostamatinib decrease the Severity of Colonic Mucosal Damage in a Rodent Model of Colitis?
Fostamatinib reduced the inflammatory damage in the experimental colitis. This effect may be due to suppression of TNFα, T-lymphocytes, and neutrophils in colonic mucosa via suppression of Syk. Fostamatinib may be an appropriate treatment alternative for ulcerative colitis. Further clinical studies are required to support this.
Patient-oriented interventions in addition to logistic support have a positive effect on diabetic patient outcomes.